Lantern Pharma(LTRN)
DALLAS, TXPharmaceutical
Focus: Lantern Pharma is an AI-driven oncology company focused on personalized cancer therapy, leveraging artificial intelligence to identify patient populations most likely to benefit from its drug candidates. The company is publicly traded (NASDAQ: LTRN) with a pipeline spanning lung cancer, breast cancer, prostate cancer, glioblastoma, and lymphomas.
Profile data last refreshed 15h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Lantern Pharma
AI assessmentNot HiringNo open roles listed right now. Follow Lantern Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT06132503Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Phase 1Help build intelligence for Lantern Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.